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Early T cell precursor acute lymphoblastic leukemia
(ETP-ALL) is an aggressive subtype of ALL distin-
guished by stem-cell-associated and myeloid tran-
scriptional programs. Inactivating alterations of Poly-
comb repressive complex 2componentsare frequent
in human ETP-ALL, but their functional role is largely
undefined. We have studied the involvement of Ezh2
in a murine model of NRASQ61K-driven leukemia
that recapitulates phenotypic and transcriptional fea-
tures of ETP-ALL. Homozygous inactivation of Ezh2
cooperatedwith oncogenic NRASQ61K to accelerate
leukemia onset. Inactivation of Ezh2 accentuated
expression of genes highly expressed in human
ETP-ALL and in normal murine early thymic progeni-
tors. Moreover, we found that Ezh2 contributes
to the silencing of stem-cell- and early-progenitor-
cell-associated genes. Loss of Ezh2 also resulted
in increased activation of STAT3 by tyrosine 705
phosphorylation. Our data mechanistically link Ezh2
inactivation to stem-cell-associated transcriptional
programs and increased growth/survival signaling,
features that convey an adverse prognosis in
patients.INTRODUCTION
Both gain and loss of function of developmental regulator Poly-
comb repressive complex 2 (PRC2) are found in cancer, including
leukemia and lymphoma. Theunderlyingmechanismsare incom-
pletely understood. PRC2 consists of the core subunits Extraem-
bryonic Ectoderm Development (EED), Suppressor of Zeste 12Ce(SUZ12), and the methyltransferase Enhancer of Zeste 2 (EZH2)
(reviewed in Laugesen and Helin, 2014). High-level expression
of EZH2 has been described in prostate cancer and other epithe-
lial malignancies (Varambally et al., 2002), and hyperactive
mutants of EZH2 have been identified in diffuse large B cell lym-
phoma (DLBCL) and follicular lymphoma (FL) (Okosun et al.,
2014; Sneeringer et al., 2010). On the other hand, EZH2 is somat-
ically inactivated in other hematological malignancies, including
myelodysplastic syndrome (MDS), myeloproliferative neoplasm
(MPN), and CALM-AF10 leukemia (Ernst et al., 2010; Grossmann
et al., 2012; Guglielmelli et al., 2011; Nikoloski et al., 2010). PRC2
components are also inactivated by mutation in T-lineage acute
lymphoblastic leukemia (ALL) (Ntziachristos et al., 2012), and
especially in the aggressive subtype early T cell precursor
(ETP)-ALL (Zhang et al., 2012a). Alterations of themethyltransfer-
ase EZH2 in particular have been linked to poor clinical outcomes
in this disease (Zhang et al., 2012a).
Data from animal models have provided some insight into the
role of PRC2 in normal development and malignancy without
resolving how both gain and loss of function of PRC2 contribute
to the development of hematologic malignancies. The PRC2
core components Ezh2, Suz12, and Eed are required for proper
differentiation of mouse embryonic stem cells (Pasini et al.,
2007; Shen et al., 2008). The causal involvement of hyperactive
Ezh2 mutations in lymphomagenesis has been demonstrated in
mice (Be´guelin et al., 2013; Caganova et al., 2013). At the same
time, Ezh2 is required for proper B and T cell development (Su
et al., 2005). Inactivation of Ezh2 is partially compensated in
some contexts by the less well-characterized methyltransferase
EZH1 (Margueron et al., 2008; Shen et al., 2008), whereas inac-
tivation of Eed leads to complete loss of the canonical PRC2
function and di- and tri-methylation of lysine 27 on histone 3
(Shen et al., 2008; Xie et al., 2014). Inactivation of Ezh2 and
Eed both impair the growth of murine models of MLL-rear-
ranged acute myeloid leukemia (AML), and this effect has
been ascribed in part to derepression of the Cdkn2a tumorll Reports 14, 1953–1965, March 1, 2016 ª2016 The Authors 1953
Figure 1. Genetic Inactivation of Ezh2 or
Eed Cooperates with NRASQ61K in the
Establishment of Murine Leukemia
(A) Experimental schema.
(B) Inactivation of Ezh2 results in global decrease
in cellular H3K27me3 (western blot).
(C) Significantly shortened survival in recipients
of Ezh2D/DCdkn2a/NRASQ61K cells compared
to floxed counterparts (n = 10 mice per group;
Kaplan-Meier analysis).
(D) Significantly shortened survival in recipients
of EedD/D Cdkn2a/ NRASQ61K cells compared
to floxed counterparts (n = 10 mice per group;
Kaplan-Meier analysis).
(E) Direct comparison shows similar survival in
recipients of Ezh2D/D Cdkn2a/ NRASQ61K cells
and recipients of EedD/D Cdkn2a/ NRASQ61K
cells (n = 10 mice per group; Kaplan-Meier anal-
ysis). NS, not significant.
See also Figures S1 and S2.suppressor encoding p16ink4a and p19arf (Neff et al., 2012; Shi
et al., 2013). In contrast, inactivation of Ezh2 in mice has led
to T cell leukemia (Simon et al., 2012) and MDS/MPN-like con-
ditions (Muto et al., 2013). To better understand how PRC2
functions as a tumor suppressor in ETP-ALL, we developed a
murine model that recapitulates features of human ETP-ALL
and directly compared leukemias with and without inactivation
of Ezh2 and Eed.
RESULTS
NRASQ61K-Expression in Cdkn2a/ Stem/Progenitor
Cells Cooperates with Homozygous Ezh2 or Eed
Inactivation in Leukemogenesis
Human ETP-ALL is an aggressive subtype of ALL and has been
linked to a stem-cell-like gene-expression program (Zhang
et al., 2012a). Genetic changes occurring in ETP-ALL are hetero-
geneous, with inactivating mutations of PRC2-components
occurring frequently and being linked to poor clinical outcomes
(Zhang et al., 2012a). We sought to study the role of Ezh2 in a
mouse model mediated by genetic alterations found in human
ETP-ALL. Many cases of ETP-ALL have alterations that directly
(e.g., oncogenic mutations) or indirectly (e.g., NF1-inactivation)
activate RAS signaling.Cdkn2amutations/deletions are encoun-
tered in a subset of ETP-ALL. Among64ETPcases in theSt. Jude
study, there are 11 NRAS mutated ETP cases. 5 of the 11 NRAS1954 Cell Reports 14, 1953–1965, March 1, 2016 ª2016 The Authorsmutant ETP cases have alterations in
at least one PRC2 component (Zhang
et al., 2012a).
To model human ETP-ALL, we intro-
duced oncogenic NRASQ61K and a
self-excising hit-and-run Cre or an inert
GFP-expressing control vector (MSCV-
ires-GFP = MIG) into Ezh2f/f Cdkn2a/
ROSA26lox-Stop-loxYFP lineage-nega-
tive, SCA1-positive, and KIT-positive
(LSK) cells (Neff et al., 2012; Serranoet al., 1996; Srinivas et al., 2001). Cells were expanded in the
presence of cytokines promoting lymphoid development (SCF,
FLT3L, and IL7) on OP9-DL1, a feeder cell line providing a Notch
signal by expressing Delta-like 1 ligand.We chose a timewindow
of 14 days to allow for expansion of cells and to approximate the
time window (Schmitt and Zu´n˜iga-Pfl€ucker, 2002) reported to
allow for T-lineage differentiation from immature hematopoietic
cells using OP9-DL1 cells (Figure 1A). Cells grown in this manner
for 14 days demonstrated a phenotype consistent with murine
double-negative (DN) 1 and 2 cells in the setting of Ezh2 inactiva-
tion, whereas the floxed counterparts showed a majority of cells
progressing to the DN3 stage (Figures S1A–S1C). Cells also had
a surface marker profile consistent with human ETP leukemia,
with subsets staining positive forMAC1 and/orGR1 (Figure S1D),
CD5 (Figure S1E), and KIT (Figure S1F). Ezh2f/f and Ezh2D/D
Cdkn2a/ NRASQ61K cells were transplanted into recipient
mice to interrogate their leukemogenic potential.
Cre-transduced Ezh2f/f Cdkn2a/ ROSA26lox-Stop-loxYFP
NRASQ61K cells were found to have fully excised floxed
Ezh2-sequences at the time of injection (Figure S2A). In contrast,
co-transduction of NRASQ61K and Cre into LSK cells with an
intact Cdkn2a locus (Ezh2f/f Cdkn2a+/+ LSK cells) resulted in
outgrowth of incompletely Ezh2-excised cells (Figure S2B), and
these cells were not transplanted in vivo. We documented loss
of EZH2 in Ezh2D/D Cdkn2a/ NRASQ61K cells at the protein
level (Figure S2C). Excision of floxed Ezh2 sequences led to
Figure 2. NRASQ61K Leukemia Has Pheno-
typic Features of ETP-ALL and Ezh2 Con-
trols a Gene Expression Program Charac-
teristic of ETP-ALL and of Physiologic
Murine Early Thymic Precursors
(A) Higher proportion of cells double positive
for myeloid markers MAC1 and GR1 in Ezh2D/D
Cdkn2a/ NRASQ61K cells compared to floxed
counterparts. Non-significant trend toward higher
MAC1/GR1 double positive cells in EedD/D
Cdkn2a/ NRASQ61K cells compared to floxed
counterparts.
(B) A majority of splenic NRASQ61K leukemic
blasts are CD44+/CD25 in all groups.
(C and D) Comparable subset positive expression
of CD5 (C) and KIT (D) in all three groups.
(E) Genes highly expressed in human ETP-ALL
compared to typical T-ALL are transcriptionally
enriched in vivo in Ezh2D/D Cdkn2a/NRASQ61K
cells compared to floxed counterparts.
(F) Genes highly expressed in mouse DN1 cells
compared to DP cells (‘‘DN1vsDP_up’’ gene set)
are transcriptionally enriched in vivo in Ezh2D/D
Cdkn2a/ NRASQ61K cells.
(G) Genes that acquire H3K27me3 in the transition
from the DN1 to the DP stage (‘‘DP_only_
H3K27me3’’ gene set) are transcriptionally en-
riched in vivo in Ezh2D/D Cdkn2a/ NRASQ61K.
(H) ChIP-seq peaks in physiological DN1 and DP
cells visualized for the genomic locus for the stem
cell-associated late HoxA cluster as an examples
of genes that acquire H3K27me3 in the develop-
mental transition fromDN1 to DP (data fromZhang
et al., 2012b).
Error bars represent SD. *p < 0.05. NS, not sig-
nificant. See also Figure S3.globally reduced H3K27me2 (Figure S2D) and H3K27me3 (Fig-
ure 1B) in Ezh2D/D Cdkn2a/ NRASQ61K cells compared to
Ezh2f/f Cdkn2a/ NRASQ61K cells.
Transplantation of NRASQ61K-transduced cells resulted in
leukemia with 100% penetrance in the presence or absence of
functional Ezh2; however, inactivation of Ezh2 resulted in signif-
icantly shortened latency (Figure 1C). Sustained complete
excision of floxed Ezh2 sequences was documented in vivo by
RNA-seq (Figure S2E) and by qRT-PCR (Figures S2F and
S2G). Inactivation of the PRC2 component Eed (EedD/D
Cdkn2a/ NRASQ61K) also resulted in significantly shortened
leukemia latency (Figure 1D). Latency of Eed-inactivated and
Ezh2-inactivated NRASQ61K leukemias on a Cdkn2a/ back-
ground was very similar in a direct comparison (Figure 1E).
Excision of floxed Eed sequences was confirmed by qRT-PCR
(Figure S2H). Inactivation of Eed resulted in an expected global
cellular loss of H3K27me3 (Figure S2I).
NRASQ61K Leukemia Shares Phenotypic Features with
Human ETP-ALL
In addition to a shortened latency for leukemias with compro-
mised PRC2 function, we observed subtle phenotypical differ-Ceences that are consistent with more aggressive and immature
disease. Recipients of Ezh2D/D Cdkn2a/ NRASQ61K cells
had significantly higher peripheral white blood cell counts and
a trend toward lower hemoglobin and platelet counts (Fig-
ure S2J). Engraftment in the bone marrow (Figure S3A) of mori-
bund mice was also higher in the Ezh2D/D and EedD/D groups
compared to floxed counterparts. There was no clear trend for
splenic involvement: spleen weight (Figure S3B) was similar in
the Ezh2D/D and slightly but significantly lower in the EedD/D
group; however, engraftment was higher in the Ezh2D/D and
EedD/D groups compared to floxed counterparts (Figure S3C).
We found a non-significant trend toward lower thymus weights
(Figure S3D) and significantly lower thymic engraftment (Fig-
ure S3E) in the Ezh2D/D and EedD/D groups, which is in keeping
with a low frequency of mediastinal tumors in human ETP-ALL
(Coustan-Smith et al., 2009).
Floxed, Ezh2D/D, and EedD/D splenic blasts had a similar im-
munophenotype, with minor differences. All three groups had a
similar proportion of blasts with at least one myeloid marker
(MAC1 or GR1; Figure S3F). Ezh2D/D blasts had a higher propor-
tion of blasts double positive for both MAC1 and GR1 (Fig-
ure 2A). Common to all three groups was a majority of leukemiall Reports 14, 1953–1965, March 1, 2016 ª2016 The Authors 1955
Figure 3. Differentiation Block Is Partially
Reversed in the Thymus in Cdkn2a/
NRASQ61K Cells with a Fully Functional
PRC2 Complex, but Not in Ezh2D/D and
EedD/D Cells
(A) Significantly higher proportion of CD4/8
double positive (DP) fluorochrome-positive blasts
in the thymus of recipients of Cdkn2a/
NRASQ61K cells with a fully functional PRC2.
(B) Significantly lower proportion of CD44/
CD25 blasts in the thymus of recipients of
Ezh2D/D and EedD/D Cdkn2a/ NRASQ61K
cells.
(C) Significantly higher proportion of CD44+/
CD25 blasts in the thymus of recipients
of Ezh2D/D and EedD/D Cdkn2a/ NRASQ61K
cells.
(D) Similar proportion of CD4 single-positive
(SP) blasts in the thymus of recipients of cells
with a fully functional PRC2 and recipients
of Ezh2D/D and EedD/D Cdkn2a/ NRASQ61K
cells.
(E) Similar proportion of CD8 single-positive
blasts in the thymus of recipients of cells with a
fully functional PRC2 and recipients of Ezh2D/D
and EedD/D Cdkn2a/ NRASQ61K cells.
(F) Similar proportion of KIT positive blasts in the thymus of recipients of cells with a fully functional PRC2 and recipients of Ezh2D/D and EedD/D Cdkn2a/
NRASQ61K cells (with the EedD/D group showing a small but significant increase compared to Ezh2D/D group).
Error bars represent SD. *p < 0.05. NS, not significant.cells with a CD44-positive/CD25-negative surface phenotype
(Figure 2B; similar to thymic DN1 cells). We also observed subset
positivity for the lymphoid marker CD5 (Figure 2C) and for KIT
(Figure 2D). The phenotype of Ezh2f/f and Ezh2D/D Cdkn2a/
NRASQ61K leukemias was also similar with respect to expres-
sion of additional lymphoid surface markers (Figures S3G and
S3H). However, Ezh2f/f cells had a higher proportion of CD8
single-positive cells (Figures S3I–S3L), consistent with a less
stringent differentiation block. In summary, NRASQ61K-trans-
formed murine LSK cells with an inactivated Cdkn2a locus
form an acute leukemia in mice that shares phenotypic features
with human ETP-ALL.
Ezh2-Inactivation Accentuates Transcriptional
Programs Characteristic of ETP-ALL and of Normal
Murine Early Thymic Precursors
To characterize the effects of Ezh2-inactivation on a molecular
level, we performed global expression profiling by RNA-seq of
Ezh2D/Dand Ezh2f/f Cdkn2a/ NRASQ61K cells both in vitro
prior to transplantation and in vivo after harvest from leukemic
spleens. Genes with increased expression in human ETP-ALL
compared to typical T-lineage ALL (Zhang et al., 2012a) were
significantly enriched in Ezh2D/D cells compared to Ezh2f/f coun-
terparts (Figure 2E in vivo; Figure S3M in vitro). We also evalu-
ated the expression of genes characteristic of purified, untrans-
formed murine CD4/CD8 DN1 ETP cells compared to CD4/CD8
DP cells (Zhang et al., 2012b). This gene set was found to be en-
riched in Ezh2D/D compared to Ezh2f/f Cdkn2a/ NRASQ61K
cells in vivo (Figure 2F) and prior to transplantation (Figure S3N).
We next investigated the link between the gene expression pro-
file observed in Ezh2D/D Cdkn2a/ NRASQ61K cells and genes1956 Cell Reports 14, 1953–1965, March 1, 2016 ª2016 The Authorsthat acquire H3K27me3 in the developmental transition from
DN1 to DP (‘‘DP_only_H3K27me3’’) as described previously
(Zhang et al., 2012b). These PRC2 target genes are enriched in
DN1 cells compared to DP cells (Figure S3O), consistent with a
role for H3K27me3 in themaintenance of gene-repression during
thymocyte development. We found this set of PRC2 target genes
to also be enriched following Ezh2-inactivation in Cdkn2a/
NRASQ61K cells (Figure 2G in vivo; Figure S3P in vitro). Impor-
tantly, one genomic site that is transcriptionally silenced in the
transition from DN1 to DP cell and acquires H3K27me3 in this
transition is the distal HoxA cluster (Figure 2H). Thus, Ezh2 inac-
tivation results in enhanced expression of genes that are highly
expressed in human ETP-ALL and in murine purified DN1 ETP
cells. Furthermore, Ezh2 inactivation promotes expression of
genes that acquire H3K27me3 in normal T-lineage development.
Differentiation Block of Cdkn2a/ NRASQ61K Cells Is
Partially Relieved by Thymic Microenvironment in Cells
with Intact PRC2, but Not Cells with Ezh2 or Eed
Inactivation
Flow cytometric analysis of thymic fluorochrome-positive blasts
demonstrated a significant proportion of CD4/CD8 DP blasts in
recipients of cells with intact PRC2 function, but not recipients
of Ezh2D/D Cdkn2a/ NRASQ61K or EedD/D Cdkn2a/
NRASQ61K blasts (Figure 3A). PRC2-compromised cells also
showed a lower proportion of CD44/CD25 blasts (Figure 3B)
and a significantly higher proportion of CD44+/CD25 (DN1-
like) blasts (Figure 3C). All groups had similar levels of CD4 sin-
gle-positive blasts (Figure 3D) and CD8 single-positive blasts
(Figure 3E) in the thymus. Levels of KIT were slightly, but signif-
icantly, higher in recipients of Ezh2D/D cells (Figure 3F). These
Figure 4. H3K27me3 Changes Correlate with Transcriptional Differences between Ezh2f/f and Ezh2D/D Cdkn2a/ NRASQ61K Cells
(A)H3K27me3differencesbetweenEzh2f/fandEzh2D/DCdkn2a/NRASQ61K cells (top5,000genes). The ranked list of the top5,000genes is provided in TableS1.
(B) Enrichment of genes with decrease in H3K27me3 in Ezh2D/D Cdkn2a/ NRASQ61K cells.
(C) Significant overlap between genes with loss of H3K27me3 after inactivation of Ezh2 and genes acquiring H3K27me3 in the transition from mouse DN1 to
mouse DP cells.
See also Figure S7.data show that the thymic microenvironment partially alleviates
the differentiation block of Cdkn2a/ NRASQ61K cells in the
presence of an intact PRC2 complex. The data further support
the concept that PRC2 is important for thymic T cell differentia-
tion and that impaired PRC2 function results in a differentiation
block.
Genes Preferentially Marked by H3K27me3 in Ezh2f/f
Cdkn2a/ NRASQ61K Are Transcriptionally Enriched in
Ezh2D/D Cells
We performed chromatin immunoprecipitation sequencing
(ChIP-seq) for H3K27me3 on cultured leukemias from recipients
of Ezh2f/f and Ezh2D/D Cdkn2a/ NRASQ61K cells. There was
notable loss of K27me3 signal in Ezh2-inactivated cells at loci
with strong positive signal in floxed counterparts (Figure 4A).
UsingMACS2 (Fenget al., 2012),we identified59,289peaks (cor-
responding to 7,334 genes) for theEzh2f/f Cdkn2a/NRASQ61K
cells compared to 660 peaks (corresponding to 259 genes) in the
Ezh2D/DCdkn2a/NRASQ61K cells (Table S1). TheH3K27me3-
associated genes within both groups showed highly significant
overlap with MSigDb gene sets consisting of established PRC2
targets, and the most significant hit for both groups in the entire
MSigDb database was ‘‘BENPORATH_ES_WITH_H3K27ME3’’
(data not shown). A gene set defined as genes with differentially
higher H3K27me3 signal in floxed cells was significantly enriched
in Ezh2D/D Cdkn2a/ NRASQ61K cells in vivo (Figure 4B) and
prior to injection (data not shown). We found significant overlap
between genes losing H3K27me3 in Ezh2-inactivated cells and
genes gaining H3K27me3 in the transition from DN1 to DP cells
(Zhang et al., 2012b) (Figure 4C).
Inactivation of Ezh2 Accentuates a Stem- and
Progenitor-Associated Transcriptional Program
Since ETP-ALL has been linked to stem cell transcriptional pro-
grams, we asked if inactivation of Ezh2 leads to enrichment ofCestem-cell-associated transcriptional programs. We found that
genes upregulated in human HSC (data from Novershtern
et al., 2011; Figure 5A) and genes upregulated in murine HSC
(data from Chambers et al., 2007; Figure 5B) compared to
more mature cell types are enriched in Ezh2D/D Cdkn2a/
NRASQ61K cells in vivo. We found enrichment of the same
gene sets in Ezh2D/D Cdkn2a/ NRASQ61K cells prior to injec-
tion (data not shown) and interestingly also in publically available
expression data in Ezh2D/D compared to Ezh2f/f murine granulo-
cyte-macrophage progenitors (GMPs) (data not shown) (Muto
et al., 2013). These data provide additional evidence that Ezh2
contributes to silencing of a stem-cell- and early-progenitor-
cell-associated program in leukemic and normal hematopoiesis.
We further confirmed increased expression of two stem-cell-
and early-progenitor-cell-associated genes, HoxA9 (Figure 5C)
and Bmi1 (Figure 5D), in response to Ezh2 inactivation in vivo.
These loci are PRC2 targets in Ezh2f/f Cdkn2a/ NRASQ61K
cells (Figure 5E). In summary, these data show that develop-
mental transcriptional downregulation of stem-cell- and early-
progenitor-cell-associated genes is accompanied by gain of
H3K27me3 at a number of critical loci. Genetic inactivation of
Ezh2 leads to impairment in the developmentally regulated
downregulation of these stem-cell- and early-progenitor-cell-
associated genes. Thus, acquisition of the Ezh2-catalyzed
H3K27me3 is associated with transcriptional silencing of stem-
cell-associated programs during hematopoietic differentiation.
Forced Expression of HoxA9 Recapitulates Key Aspects
of PRC2 Inactivation
We confirmed that HoxA9 is indeed a direct PRC2 target in our
system using ChIP followed by qPCR (Figure 6A). Furthermore,
genes with expression levels that correlate with HOXA9
expression in T-ALL (including ETP-ALL) and in acute myeloid
leukemia were identified using Pearson correlation analysis on
two independent publically available human leukemia datasetsll Reports 14, 1953–1965, March 1, 2016 ª2016 The Authors 1957
Figure 5. PRC2 Controls a Stem Cell/Early
Progenitor Cell Gene Expression Program
in Hematopoietic Differentiation
(A) Genes highly expressed in human hematopoi-
etic stem cells are enriched in vivo in Ezh2D/D
Cdkn2a/ NRASQ61K cells compared to their
floxed counterparts.
(B) Genes highly expressed in mouse hematopoi-
etic stem cells are enriched in vivo in Ezh2D/D
Cdkn2a/ NRASQ61K cells compared to their
floxed counterparts.
(C) HoxA9 is significantly higher expressed in vivo
in Ezh2D/D Cdkn2a/ NRASQ61K cells compared
to their floxed counterparts (Ezh2f/f n = 3, Ezh2D/D
n = 4, qRT-PCR).
(D) Bmi1 is significantly higher expressed in vivo in
Ezh2D/D Cdkn2a/ NRASQ61K cells compared
to their floxed counterparts (Ezh2f/f n = 3, Ezh2D/D
n = 4, qRT-PCR).
(E) ChIP-seq peaks visualized for the genomic lo-
cus for the stem-cell-associated late HoxA-cluster
and the stem-cell-associated gene Bmi1 as ex-
amples of genes that lose H3K27me3 after inac-
tivation of Ezh2.
Error bars represent SD. *p < 0.05.(GSE28703, Zhang et al., 2012a; and GSE689, Verhaak et al.,
2009), as previously described (Velu et al., 2014). Both gene
sets clustered murine LSKs, GMPs, and common myeloid
progenitors (CMPs) with 100% accuracy, based on published
expression data (Krivtsov et al., 2006, 2013) (Figure S4A). Genes
correlated with HOXA9 in T-ALL or AML were significantly
enriched in Ezh2D/D versus Ezh2f/f Cdkn2a/ NRASQ61K cells
in vivo (Figures 6B and 6C) and prior to injection (Figures S4B
and S4C).
We next asked if the elevated expression of the late HoxA-
cluster gene HoxA9 has functional relevance in our leukemia
model. We coexpressed HoxA9-IRES-GFP or empty-vector-
IRES-GFP with NRASQ61K in Ezh2f/f Cdkn2a/ LSK cells. Cells
were expanded on OP9-DL1 stroma in the presence of cyto-
kines, and transplanted into syngeneic, sublethally irradiated
recipients. Leukemia latency was shortened significantly in the
recipients of HoxA9-overexpressing cells (Figure 6D). Overex-
pression of HoxA9 was confirmed by qRT-PCR prior to injection
(Figure 6E). We also noted enrichment of HOXA9-correlated
genes in human ETP-ALL with genomic alteration in a PRC21958 Cell Reports 14, 1953–1965, March 1, 2016 ª2016 The Authorscomponent compared to ETP-ALL
without genomic alteration in PRC2 com-
ponents (Figures S4D and S4E; data from
Zhang et al., 2012a).
Ezh2D/D Cdkn2a/ NRASQ61K
Leukemias Show Accentuated
Growth and Survival Signaling
While increased expression of a stem cell
program, that includes HOXA cluster
genes, explains a substantial portion
of the phenotypic and transcriptional
consequences of PRC2 inactivation, wealso noted transcriptional evidence of increased growth and sur-
vival signaling in our transcriptome analysis. Dysregulated
growth and survival signaling have previously been reported as
a consequence of PRC2 inactivation. We performed gene set
enrichment analysis (GSEA) in our ETP-ALL model and noted
significant enrichment of growth factor and cognate receptor
gene transcripts in Ezh2D/D Cdkn2a/ NRASQ61K leukemias
compared to floxed counterparts in vivo (Figure S5A) and
in vitro (data not shown). In NF1 sarcomas, PRC2 inactivation
has recently been linked to hyperactive RAS signaling and may
occur at the chromatin level rather than through defined
enhanced phospho-signaling (De Raedt et al., 2014). Indeed,
we found RAS signatures accentuated in our model upon Ezh2
inactivation (Figure S5B and data not shown). In addition, genes
downregulated in NF1-associated sarcoma cell lines by reintro-
duction of SUZ12 are enriched in our model upon Ezh2-inactiva-
tion (Figure S5C). Many of the genes deregulated in our model
are documented targets of the STAT3 signaling pathway (Figures
S5D and S5E). Furthermore, STAT3 is a critical component in
myeloid development (McLemore et al., 2001; Shimozaki et al.,
Figure 6. Accentuation of a Developmen-
tally Regulated HOXA9-Correlated Gene
Expression Program in Ezh2D/D Cdkn2a/
NRASQ61K Cells
(A) Increased H3K27me3 enrichment asmeasured
by ChIP-qPCR at loci for HoxA9 and the docu-
mented PRC2 target Olig2, but not b-actin, in
Ezh2f/f Cdkn2a/ NRASQ61K cells compared to
Ezh2D/D Cdkn2a/ NRASQ61K cells.
(B) Genes correlated with HOXA9 expression in
T-ALL are transcriptionally enriched in vivo in
Ezh2D/DCdkn2a/NRASQ61K cells compared to
their floxed counterparts.
(C) Genes correlated with HOXA9 expression in
AML are transcriptionally enriched in Ezh2D/D
Cdkn2a/ NRASQ61K cells compared to their
floxed counterparts.
(D) Forced expression of HoxA9 synergizes with
NRASQ61K in leukemogenesis in the presence of
an intact Ezh2 locus.
(E) Increased expression of HoxA9 in MSCV-
HoxA9-i-GFP (HOXA9) compared to MSCV-i-GFP
(MIG) transduced cells (qRT-PCR).
Error bars represent SD. *p < 0.05. See also
Figure S4.1997), in keeping with amyeloid surfacemarker phenotype in the
NRASQ61K model. We therefore performed phospho-western
blotting and documented increased phosphorylation of STAT3
on tyrosine residue 705 (Figure 7A). This raised the intriguing
possibility that PRC2 mutant ETP-ALL might be susceptible to
JAK/STAT pathway inhibition even in the absence of mutations
directly involved in the pathway.
Ezh2D/D Cdkn2a/ NRASQ61K Cells Respond to JAK/
STAT Pathway Inhibition
Phosphorylation of STAT3 and STAT5 has recently been docu-
mented in a majority of human ETP-ALL, and was reversed by
the JAK1/2 inhibitor ruxolitinib (Maude et al., 2015). Activating
mutations in cytokine receptors that signal through JAK/STAT
are found at substantial frequencies in human ETP-ALL,
providing a rationale for the use of ruxolitinib in these subtypes.
While our model does not carry any mutations that would be ex-
pected to signal through JAK/STAT, the increased STAT3Y705
phosphorylation led us to assess whether this pathway is func-
tionally important in our ETP-ALL model. We exposed Ezh2f/f
and Ezh2D/D Cdkn2a/ NRASQ61K cells in vitro to ruxolitinib
and observed that ruxolitinib reverses STAT3Y705 phosphoryla-
tion in both cell types (Figure 7B). In addition, ruxolitinib inhibited
in vitro growth of Ezh2D/D Cdkn2a/ NRASQ61K (Figure 7C).
However, the increased STAT3Y705 phosphorylation in Ezh2D/D
Cdkn2a/ NRASQ61K did not confer hypersensitivity to ruxoli-
tinib. Rather, loss of PRC2 appeared to be a possiblemechanism
of resistance, with higher doses of ruxolitinib being required to
fully block STAT3Y705 phosphorylation and affect cell growth.
Similar results were found in a second set of leukemias (Fig-
ure S5F). EedD/D Cdkn2a/ NRASQ61K cells likewise had
accentuated phospho-STAT3Y705 (Figure S5G) and showed
cell growth inhibition in response to ruxolitinib (Figure S5H). To
further investigate the role of JAK/STAT signaling in our model,
we evaluated the effect of two published STAT3 inhibitors,CeLLL12 (Liu et al., 2010) and BP-1-102 (Zhang et al., 2012c).
Both inhibited STAT3Y705 phosphorylation in Ezh2D/D
Cdkn2a/ NRASQ61K cells and interfered with their growth
(Figures S5I and S5J). In summary, these data provide strong
evidence for the functional importance of JAK/STAT signaling
in our model and raise concerns that PRC2 loss may
make clinically meaningful inhibition of JAK/STAT signaling
more challenging.
De-repression of Il6ra Contributes to Hyperactive JAK/
STAT Signaling in T-ALL with PRC2 Inactivation
Finally, to better understand the mechanistic basis of the
increased JAK/STAT signaling in Ezh2D/D versus Ezh2f/f
Cdkn2a/ NRASQ61K cells, we first asked whether STAT3 is
transcriptionally upregulated in response to Ezh2 inactivation.
Ezh2D/D cells displayed slightly higher levels of Stat3mRNA (Fig-
ure S6A), though the effect was small and not statistically signif-
icant. We therefore assessed the responsiveness of our paired
leukemias to several growth factors (FLT3L, HGF, IL6, IL7, and
SCF). We found no difference in the responsiveness to FLT3L,
HGF, and SCF (Figure S6B). However, both IL6 and IL7 led to
exaggerated STAT3Y705 phosphorylation, with a very pro-
nounced increase for IL6 (Figures 7D and S6B). Il6ra was signif-
icantly higher expressed in Ezh2-inactivated cells compared to
floxed counterparts (Figure 7E). This finding correlates with
higher levels of H3K27me3 at the Il6ra locus in Ezh2f/f compared
to Ezh2D/D Cdkn2a/ NRASQ61K leukemia by ChIP-seq (Fig-
ure 7F). Il6ra is transcriptionally downregulated in the transition
from normal DN1 cells to DP cells, and the Il6ra locus acquires
H3K27me3 in DP cells (Figure 7F) (Zhang et al., 2012b). The
IL6R is also significantly higher expressed in ETP-ALL compared
to typical ALL in the St. Jude study (Zhang et al., 2012a) (Fig-
ure 7G). Increased STAT3Y705 phosphorylation due to IL6 hy-
per-responsiveness thus contributes to increased JAK/STAT
signaling in Ezh2D/D T-ALL and may be a mediator of drugll Reports 14, 1953–1965, March 1, 2016 ª2016 The Authors 1959
Figure 7. Ezh2-Inactivation Leads to Accentuated Growth/Survival Signaling in NRASQ61K Leukemia
(A) Phospho-western blotting reveals increased STAT3Y705 phosphorylation in Ezh2D/D Cdkn2a/ NRASQ61K cells compared to their floxed counterparts.
(B) STAT3Y705 phosphorylation is inhibited by ruxolitinib in a dose-dependent manner in Ezh2f/f Cdkn2a/ NRASQ61K and Ezh2D/D Cdkn2a/
NRASQ61K cells.
(C) Growth of Ezh2f/f Cdkn2a/ NRASQ61K and Ezh2D/D Cdkn2a/ NRASQ61K cells is inhibited by ruxolitinib in a dose-dependent manner.
(D) Exaggerated response to IL6 stimulation in Ezh2D/D Cdkn2a/ NRASQ61K cells growth factor starved for 8 hr.
(E) Increased level of Il6ra expression in Ezh2D/D Cdkn2a/ NRASQ61K cells.
(F) Increased H3K27me3 at the Il6ra locus in Ezh2f/f Cdkn2a/NRASQ61K cells compared to Ezh2D/DCdkn2a/NRASQ61K cells and in normal mouse DP cells
compared to DN1 cells.
(G) Significantly increased IL6RA expression in human ETP-ALL compared to non-ETP ALL.
Error bars represent SD. *p < 0.05. NS, not significant. See also Figures S5 and S6.resistance to JAK1/2 inhibition in this model. Interestingly, we
also observed an increase in STAT3Y705 phosphorylation in
Ezh2f/f pre-leukemic and leukemic cells in HoxA9-overexpress-
ing cells (Figure S6C), pointing toward a potential additional
link between early hematopoietic transcriptional programs and
accentuated signaling in our model.
DISCUSSION
The effects of PRC2 hyper- and hypoactivity in human disease
andmodel systems have been contradictory. Hyperactive alleles
of EZH2 observed in human lymphomas contribute to differenti-
ation block and lymphomagenesis inmousemodels. Inactivation
of Ezh2 impedes the progression ofMLL-AF9 driven leukemia in
mice (Neff et al., 2012; Tanaka et al., 2012), and inactivation of
Eed is not tolerated (Neff et al., 2012; Shi et al., 2013). On the
other hand, alterations in PRC2 components thought to be inac-
tivating are associated with hematologic malignancies in hu-
mans and mice. Recently, PRC2-mediated control of genes
with opposing function on cellular growth has been demon-
strated in normal murine hematopoiesis (Xie et al., 2014). Here,
we provide evidence for the functional importance of Cdkn2a1960 Cell Reports 14, 1953–1965, March 1, 2016 ª2016 The Authorsas an Ezh2 downstream target in acute leukemia. Furthermore,
our findings indicate that Ezh2 has a functional role in the devel-
opmental silencing of a gene expression program associated
with the transition of early thymic precursors to DP thymocytes
and a transcriptional program associated with stem cells and
early progenitor cells in normal hematopoiesis. We validated
functional importance for one such gene, HoxA9, using an over-
expression approach. Finally, we show that the prognostic impli-
cation of Ezh2 alterations is in part explained by deregulated
growth and survival signaling through STAT3, a signaling alter-
ation also associated with other poor prognosis subsets of acute
leukemia.
Control of Cdkns by Ezh2
Cdkn2a is an established binding target of PRC2 and PRC1. Pre-
vious studies have demonstrated that the adverse effects on
cellular growth resulting from inactivation of Eed and other Poly-
comb-group genes in hematopoiesis can be rescued in part by
genetic inactivation of Cdkn2a (Hidalgo et al., 2012; Oguro
et al., 2012; Xie et al., 2014). Here, we report that genetic inacti-
vation of Cdkn2a allows for the establishment of Ezh2 null acute
leukemia. In human ETP-ALL, PRC2 components are frequently
altered, butCDKN2A is deleted in aminority of cases (Haydu and
Ferrando, 2013; Zhang et al., 2012a). These data suggest that in
human ETP-ALL, CDKN2A may be controlled by mechanisms
other than deletional inactivation. In accord with this speculation,
CDKN2A is a documented target of epigenetic silencing in hu-
man leukemia. It will be important to study how this locus is
controlled in human ETP-ALL with impaired PRC2-function.
Candidate mechanisms include DNA methylation, H3K9 methyl-
ation, and PRC1-dependent silencing.
Ezh2 Contributes to Developmental Silencing of Genes
Expressed in Early T Cell Precursors and in Stem Cells
and Early Progenitor Cells
The developmental transition from early thymic precursor to DP
thymocyte has been well characterized. ETPs have been docu-
mented to retain myeloid development potential that is progres-
sively lost in the transition to DP cell (Bell and Bhandoola, 2008;
Wada et al., 2008). The developmental transition is accompanied
by the acquisition of H3K27me3 at many loci, including stem-
cell-associated genes such as late HoxA-cluster genes and
the receptor for IL6 (Zhang et al., 2012b). These findings are in
keeping with a recently described role for PRC2 and Ikaros in
regulating thymocyte development (Oravecz et al., 2015). In
our NRASQ61K leukemia model, Ezh2-inactivation results
in enriched expression of genes associated with DN1 cells,
and therefore contributes to a differentiation block.
Ezh2 Contributes to Developmental Silencing of Genes
Highly Expressed in Early Hematopoiesis
We found that genes expressed in early hematopoiesis, such as
HoxA9, Bmi1 (Figure 5E), and Gata2 (data not shown), are PRC2
targets in our model. We also noted that these genes are
silenced and acquire H3K27me3 in the developmental transition
from immature LSK to GMP cells in published data (data not
shown) (Bernt et al., 2011). There is significant overlap in the
genes acquiring H3K27me3 in the transition from LSK to GMP
and in the transition from DN1 to DP, further supporting a role
for Ezh2/PRC2 in the silencing of early transcriptional programs
in hematopoietic differentiation (Figure S7). Epigenetic mecha-
nisms have been implicated in the differentiation-associated
silencing of genes highly expressed in the stem/early progenitor
compartment. Examples are the H3K9 methyltransferase G9a
(Chen et al., 2012) and the histone demethylase LSD1/KDM1a
(Kerenyi et al., 2013). Interestingly, G9A (Mozzetta et al., 2014)
and LSD1 have both been reported to collaborate with EZH2
(Tsai et al., 2010). In human leukemia, stem cell gene expression
signatures have been linked to inferior outcomes (Eppert et al.,
2011). ETP-ALL has previously been shown to express a stem
cell program compared to non-ETP T-ALL (Zhang et al.,
2012a). Our findings show that inactivation of the PRC2 compo-
nent Ezh2 directly results in the accentuation of an expression
program associated with stem cells and early progenitor cells,
suggesting a causal link. This is further supported by our findings
that overexpression of the stem cell and early progenitor tran-
scriptional regulator HoxA9 recapitulates many aspects of
PRC2 impairment in this model, including the key features of a
more immature and accelerated disease in vivo. Despite its clear
functional relevance, HoxA9 is likely not the only component ofCethis stem cell transcriptional program mediating the effect of
PRC2 compromise, and other PRC2 target genes are attractive
candidates for further study. A better understanding of the regu-
lation of stem cell programs promises the development of more
specific targeting of leukemic self-renewal, sparing normal he-
matopoietic cells.
Another model of human ETP-ALL has recently been pub-
lished using transfer of IL7Rmutants and LMO2 into purified mu-
rine DN thymocytes (Treanor et al., 2014). In this model, murine
p19/DN thymocytes rather than earlier hematopoietic progen-
itors or HSCswere the targets of transformation, and inactivation
of PRC2 components was not employed. Nonetheless, a
leukemic phenotype similar to what we describe was observed.
These findings are in keeping with the reported genetic hetero-
geneity of human ETP-ALL (Zhang et al., 2012a).
Cooperation with and Accentuation of Growth and
Survival Signaling by Inactivation of PRC2
In humans,PRC2 alterations are frequently found in clinical acute
leukemia samples with T cell/myeloid features (Grossmann et al.,
2012; Zhang et al., 2012a): For example, in the study by Zhang, 5
of the 11 NRAS-mutant and 7 out of 7 NF1 mutated ETP-ALL
cases had an alteration in at least 1 PRC2 component. Genetic
alterations impeding PRC2-function are also found in the mega-
karyoblastic leukemia (AMKL) observed in patients with Down
Syndrome (Nikolaev et al., 2013; Yoshida et al., 2013), and in ju-
venile myelo-monocytic AML (JMML), a RAS driven disease with
pathognomonic activating mutation in RAS (mostly NRAS and
KRAS) or inactivating mutations in PTPN11 or NF1 (Stieglitz
et al., 2015). Rare EZH2-alterations have been described in adult
AML (Cancer Genome Atlas Research Network, 2013) (3 out of
200 analyzed samples) and, interestingly, 2 out of these 3 sam-
ples hadco-occurringmutations inKRASorNRAS. Very recently,
cooperation between the RAS pathway and PRC2 inactivation
has also been demonstrated for some solid tumors (De Raedt
et al., 2014). These clinical and experimental data, together
with our findings, support the concept that RAS signaling coop-
erateswithPRC2compromise in cellular transformation and sup-
port the relevance of our findings to human malignancy.
JAK/STAT signaling is emerging as an important pathogenic
factor in hematopoietic malignancies. Mutations of JAK genes
or the IL7 receptor have been implicated in T-lineage ALL (De-
gryse et al., 2014; Zhang et al., 2012a). Hyperactivation of
STAT3 in response to growth factors has been linked to inferior
survival in human pediatric AML (Redell et al., 2013). Importantly,
signaling abnormalities observed in human ETP-ALL, such as
SH2B3 alterations and FLT3-ITD, have been linked to hyperac-
tive STAT3 signaling (Mead et al., 2013; Perez-Garcia et al.,
2013). Our data indicate that inactivation of Ezh2 leads to accen-
tuated phosphorylation of STAT3 on tyrosine 705, which was
associated with an increase in expression of Il6ra and hypersen-
sitive STAT3 phosphorylation in response to IL6.
Although we cannot completely rule out off-target effects, our
studies using three different inhibitors of JAK/STAT signaling
strongly suggest functional importance of JAK/STAT signaling
in our model. These data are significant in several respects: (1)
our findings directly link inactivation in an epigenetic modifier
to a biochemical signaling change; (2) PRC2 inactivationll Reports 14, 1953–1965, March 1, 2016 ª2016 The Authors 1961
simultaneously induces two poor prognostic features, a stem
cell transcriptional signature and hyperactivation of STAT3 in
response to growth factors, both independently linked to poor
outcome; and (3) while the JAK/STAT pathway is clearly active
and functional in our model, pharmacologic inhibition may be
more challenging due to increased levels of STAT phosphoryla-
tion to be overcome. In addition, possibly alternate signaling
pathways in addition to IL6/IL6RA, such as the accentuated
RAS transcriptional signature, will need to be considered.
The relationship of STAT3 signaling and EZH2 is complex.
EZH2-mediated methylation of STAT3 has been reported to be
required for STAT3Y705 phosphorylation in glioma cells (Kim
et al., 2013). In colon cancer cells, this dependency was not
found, but EZH2-mediated methylation of STAT3 was found to
be important for full induction of a subset of STAT3 target genes
(Dasgupta et al., 2015). Differences in cell type and experimental
setup may account for these differences. In our model, inactiva-
tion of Ezh2 resulted in a net positive enrichment of canonical
STAT3 target genes (Figures S5D and S5E).PRC2 As a Therapeutic Target in Cancer Therapy
Context dependence will need to be considered in the use of
drugs targeting epigenetic modifiers: pharmacologic inhibition
of EZH2 is a highly promising strategy in carefully selected target
diseases (Kim et al., 2015; Knutson et al., 2012, 2013; LaFave
et al., 2015; McCabe et al., 2012) and may have potential benefit
in the treatment ofMLL-rearranged leukemia (Danis et al., 2015;
Neff et al., 2012; Shi et al., 2013; Tanaka et al., 2012; Xu et al.,
2015). Our data provide additional evidence that rational selec-
tion of target diseases based on molecular features will be an
important determinant of success for the next generation of
epigenetic cancer therapies.
In summary, our data link inactivation of Ezh2 to stem cell
expression programs and to hyperactive cytokine signaling
through STAT3, both features known to be associated with infe-
rior clinical outcome. Our data clarify the role of Ezh2 in ETP-ALL
and support the use of therapies targeting JAK/STAT signaling,
as recently suggested by Teachy and colleagues in ETP-ALL
patient samples (Maude et al., 2015) and by Sorrentino and col-
leagues in a murine model of ETP-ALL (Treanor et al., 2014).
These prior studies did not investigate Ezh2 mutant samples.
Our data suggest that EZH2-mutated cases, which are specif-
ically associated with poor clinical outcomes (Zhang et al.,
2012a), may also potentially benefit from modulation of the
JAK/STAT signaling pathway, especially if synergistic com-
pounds can be identified. However, inhibiting the accentuated
signaling may require somewhat higher doses in PRC2 mutant
versus wild-type cells, and close attention will need to be paid
in clinical studies to ensure target inhibition in this subgroup.
Our work thus provides mechanistic insights into the association
of PRC2 with poor prognostic features, and has critical implica-
tions for the study of JAK/STAT pathway inhibition in T-ALL.EXPERIMENTAL PROCEDURES
For published plasmids used, antibodies, primer sequences, gene sets, gene
lists (Table S1), and additional experimental details, please refer to Supple-
mental Experimental Procedures.1962 Cell Reports 14, 1953–1965, March 1, 2016 ª2016 The AuthorsMice
Animals were maintained at the Animal Research Facility at the University of
Colorado Anschutz Medical Campus. Animal experiments were approved by
the Internal Animal Care and Use Committee at the University of Colorado
Denver Anschutz Medical Campus. All mice were maintained on a fully back-
crossed C57BL/6 background. See Supplemental Experimental Procedures
for mouse genotypes.
Generation of Transformed Murine Cells and Leukemia
MSCV-Ras-pgk-puro was created by subcloning human NRASQ61K se-
quences (Addgene plasmid 12543, Channing Der lab) as a BamH1 fragment
into the MSCV-puro vector. See Supplemental Experimental Procedures for
published plasmids. LINSCA1+KIT+ (LSK) cells were sorted from donor
bone marrow using aMoFlo flow sorter (Beckman Coulter) were prestimulated
in liquid culture in the presence of murine SCF (20 ng/ml), FLT3L (20 ng/ml), IL6
(20 ng/ml), and TPO (10 ng/ml) (Peprotec) and then transduced onRetronectin-
coated (Takara) plates. Cells were sorted for expression of GFP or YFP and
were selected in the presence of Puromycin on OP9-DL1 cells carrying a resis-
tance gene for puromycin in the presence of FLT3L (5 ng/ml), SCF (5 ng/ml),
and IL7 (1 ng/ml). Cells expanded for 14–21 days were then injected into
syngeneic sublethally (600 cGy) irradiated recipients. Cell growth and viability
were followed by serial cell counts. Antibodies used for flow cytometry
and immunoblot detection and qPCR primers are detailed in Supplemental
Experimental Procedures.
Western Blotting
Proteins for histone blots were harvested using acid extraction (see Supple-
mental Experimental Procedures). Proteins for non-histone protein blots
were harvested using RIPA-buffer including cOmplete mini protease inhibitor
cocktail (Roche) and, for phospho-blots, phosSTOP phosphatase inhibitor
(Roche), according to the manufacturer’s instructions. Protein was separated
on a 10% Bis-Tris Gel (Nupage; Invitrogen) and blotted using the ‘‘iblot’’ dry
transfer system (Invitrogen).
qRT-PCR
qRT-PCR was used to confirm expression of candidate genes identified by
RNA sequencing. RNA was harvested from NRASQ61K-transformed sorted
fluorochrome-positive (GFP for Ezh2f/f and Eedf/f and YFP for Ezh2D/D and
EedD/D) blasts isolated from leukemic spleens, using RNeasy mini columns
(QIAGEN). Individual RNA samples were reverse transcribed and qRT-PCR
was run in triplicate using SYBR green. Ratios were calculated using the
method described by Pfaffl (Pfaffl, 2001). The Student’s t test was performed
on log-transformed ratios of gene of interest/internal control (Hprt) using
GraphPad 6 software.
Chromatin Immunoprecipitation followed by Next-Generation
Sequencing
ChIP for H3K27me3 in murine leukemias was performed using rabbit mono-
clonal antibody (C36B11) from Cell Signaling similarly as described
elsewhere (Neff et al., 2012). ChIP DNA libraries were made using the Nugen
Ovation Ultralow system V2, followed by next-generation sequencing on an
Illumina HiSeq2000 at the Genomics Core of the University of Colorado
Anschutz Campus. See Supplemental Experimental Procedures for details
on data analysis.
Gene Set Enrichment Analysis
GSEA was performed as described previously (Subramanian et al., 2005)
using pre-ranked gene lists as input files. Construction of gene sets used is
described in Supplemental Experimental Procedures, and the gene sets are
listed in Table S1.
ACCESSION NUMBERS
The accession number for the RNA-seq and ChIP-seq data reported in this
paper is GEO: GSE76603.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.01.064.
AUTHOR CONTRIBUTIONS
E.D., T.Y., S.H.O., S.A.A, K.M.B, and T.N. designed the study. E.D., T.Y., X.Z.,
K.E., J.N.H., N.Z., S.S.R., H.X., K.M.B., and T.N. performed experiments. H.X.,
S.H.O., S.A.A., and T.N. generated reagents used in experiments. E.D., T.Y.,
K.M.B., and T.N. analyzed the data. E.D.,T.Y., T.N., and K.M.B. prepared the
manuscript with input from the other authors.
ACKNOWLEDGMENTS
We thank Karen Helm and the staff at the flow cytometry core for assistance
with FACS and cell sorting. We thank Katrina Diener and Ted Shade at the Ge-
nomics core of the University of Colorado AMC. We thank Ken Jones at the
Bioinformatics core for help with Illumina data analysis. We thank Tracy Haney
and Holly Goold for animal Husbandry. We thank Patricia Ernst and Craig Jor-
dan for critically reading the manuscript. This work was supported by National
Cancer Institute (NCI) grant K08CA154777 (T.N.); start-up funds from Univer-
sity of Colorado Denver, Section for Pediatric Hematology/Oncology, and the
Children’s Hospital ColoradoResearch Institute (T.N.); theCancer LeagueCol-
orado (T.N.); the Sidney Kimmel Foundation for Cancer Research (T.N.); Na-
tional Heart, Lung, and Blood Institute grant K08HL102264 (K.M.B.); and
NCI grant P30CA046934 (Shared Resource of the University of Colorado Can-
cer Center).
Received: April 17, 2015
Revised: November 25, 2015
Accepted: January 20, 2016
Published: February 18, 2016
REFERENCES
Be´guelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K.L., Rosen, M.,
Shen, H., Yang, S.N., Wang, L., Ezponda, T., et al. (2013). EZH2 is required
for germinal center formation and somatic EZH2 mutations promote lymphoid
transformation. Cancer Cell 23, 677–692.
Bell, J.J., and Bhandoola, A. (2008). The earliest thymic progenitors for T cells
possess myeloid lineage potential. Nature 452, 764–767.
Bernt, K.M., Zhu, N., Sinha, A.U., Vempati, S., Faber, J., Krivtsov, A.V., Feng,
Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011). MLL-rearranged leukemia is
dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78.
Caganova, M., Carrisi, C., Varano, G., Mainoldi, F., Zanardi, F., Germain, P.L.,
George, L., Alberghini, F., Ferrarini, L., Talukder, A.K., et al. (2013). Germinal
center dysregulation by histone methyltransferase EZH2 promotes lympho-
magenesis. J. Clin. Invest. 123, 5009–5022.
Cancer Genome Atlas Research Network (2013). Genomic and epigenomic
landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368,
2059–2074.
Chambers, S.M., Boles, N.C., Lin, K.Y., Tierney, M.P., Bowman, T.V., Brad-
fute, S.B., Chen, A.J., Merchant, A.A., Sirin, O., Weksberg, D.C., et al.
(2007). Hematopoietic fingerprints: an expression database of stem cells
and their progeny. Cell Stem Cell 1, 578–591.
Chen, X., Skutt-Kakaria, K., Davison, J., Ou, Y.L., Choi, E., Malik, P., Loeb, K.,
Wood, B., Georges, G., Torok-Storb, B., and Paddison, P.J. (2012). G9a/GLP-
dependent histone H3K9me2 patterning during human hematopoietic stem
cell lineage commitment. Genes Dev. 26, 2499–2511.
Coustan-Smith, E., Mullighan, C.G., Onciu, M., Behm, F.G., Raimondi, S.C.,
Pei, D., Cheng, C., Su, X., Rubnitz, J.E., Basso, G., et al. (2009). Early T-cell
precursor leukaemia: a subtype of very high-risk acute lymphoblastic
leukaemia. Lancet Oncol. 10, 147–156.CeDanis, E., Yamauchi, T., Echanique, K., Haladyna, J., Kalkur, R., Riedel, S.,
Zhu, N., Xie, H., Bernt, K.M., Orkin, S.H., et al. (2015). Inactivation of Eed
impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent
and Cdkn2a-independent mechanisms in a murine model. Exp. Hematol. 43,
930–935.
Dasgupta, M., Dermawan, J.K., Willard, B., and Stark, G.R. (2015). STAT3-
driven transcription depends upon the dimethylation of K49 by EZH2. Proc.
Natl. Acad. Sci. USA 112, 3985–3990.
De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., Helin,
K., Hornick, J.L., Mautner, V., Kehrer-Sawatzki, H., et al. (2014). PRC2 loss am-
plifies Ras-driven transcription and confers sensitivity to BRD4-based thera-
pies. Nature 514, 247–251.
Degryse, S., de Bock, C.E., Cox, L., Demeyer, S., Gielen, O., Mentens, N., Ja-
cobs, K., Geerdens, E., Gianfelici, V., Hulselmans, G., et al. (2014). JAK3 mu-
tants transform hematopoietic cells through JAK1 activation, causing T-cell
acute lymphoblastic leukemia in a mouse model. Blood 124, 3092–3100.
Eppert, K., Takenaka, K., Lechman, E.R., Waldron, L., Nilsson, B., van Galen,
P., Metzeler, K.H., Poeppl, A., Ling, V., Beyene, J., et al. (2011). Stem cell gene
expression programs influence clinical outcome in human leukemia. Nat. Med.
17, 1086–1093.
Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V.,
Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., et al. (2010). Inactivatingmutations
of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet.
42, 722–726.
Feng, J., Liu, T., Qin, B., Zhang, Y., and Liu, X.S. (2012). Identifying ChIP-seq
enrichment using MACS. Nat. Protoc. 7, 1728–1740.
Grossmann, V., Bacher, U., Kohlmann, A., Artusi, V., Klein, H.U., Dugas, M.,
Schnittger, S., Alpermann, T., Kern, W., Haferlach, T., and Haferlach, C.
(2012). EZH2 mutations and their association with PICALM-MLLT10 positive
acute leukaemia. Br. J. Haematol. 157, 387–390.
Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F.,
Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N., Jones, A.V., et al. (2011).
EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118,
5227–5234.
Haydu, J.E., and Ferrando, A.A. (2013). Early T-cell precursor acute lympho-
blastic leukaemia. Curr. Opin. Hematol. 20, 369–373.
Hidalgo, I., Herrera-Merchan, A., Ligos, J.M., Carramolino, L., Nun˜ez, J., Mar-
tinez, F., Dominguez, O., Torres, M., and Gonzalez, S. (2012). Ezh1 is required
for hematopoietic stem cell maintenance and prevents senescence-like cell
cycle arrest. Cell Stem Cell 11, 649–662.
Kerenyi, M.A., Shao, Z., Hsu, Y.J., Guo, G., Luc, S., O’Brien, K., Fujiwara, Y.,
Peng, C., Nguyen, M., and Orkin, S.H. (2013). Histone demethylase Lsd1 re-
presses hematopoietic stem and progenitor cell signatures during blood cell
maturation. eLife 2, e00633.
Kim, E., Kim, M., Woo, D.H., Shin, Y., Shin, J., Chang, N., Oh, Y.T., Kim, H.,
Rheey, J., Nakano, I., et al. (2013). Phosphorylation of EZH2 activates
STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glio-
blastoma stem-like cells. Cancer Cell 23, 839–852.
Kim, K.H., Kim, W., Howard, T.P., Vazquez, F., Tsherniak, A., Wu, J.N., Wang,
W., Haswell, J.R., Walensky, L.D., Hahn, W.C., et al. (2015). SWI/SNF-mutant
cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21,
1491–1496.
Knutson, S.K., Wigle, T.J., Warholic, N.M., Sneeringer, C.J., Allain, C.J., Klaus,
C.R., Sacks, J.D., Raimondi, A., Majer, C.R., Song, J., et al. (2012). A selective
inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Nat. Chem. Biol. 8, 890–896.
Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi,
A., Porter Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., et al. (2013).
Durable tumor regression in genetically altered malignant rhabdoid tumors by
inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 110, 7922–
7927.
Krivtsov, A.V., Twomey, D., Feng, Z., Stubbs, M.C., Wang, Y., Faber, J., Lev-
ine, J.E., Wang, J., Hahn, W.C., Gilliland, D.G., et al. (2006). Transformationll Reports 14, 1953–1965, March 1, 2016 ª2016 The Authors 1963
from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Na-
ture 442, 818–822.
Krivtsov, A.V., Figueroa, M.E., Sinha, A.U., Stubbs, M.C., Feng, Z., Valk, P.J.,
Delwel, R., Dohner, K., Bullinger, L., Kung, A.L., et al. (2013). Cell of origin de-
termines clinically relevant subtypes of MLL-rearranged AML. Leukemia 27,
852–860.
LaFave, L.M., Be´guelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A.,
Papalexi, E., Keller, M.D., Hricik, T., Konstantinoff, K., et al. (2015). Loss of
BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21,
1344–1349.
Laugesen, A., and Helin, K. (2014). Chromatin repressive complexes in stem
cells, development, and cancer. Cell Stem Cell 14, 735–751.
Liu, Y., Li, P.K., Li, C., and Lin, J. (2010). Inhibition of STAT3 signaling blocks
the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem.
285, 27429–27439.
Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C.L., Dyn-
lacht, B.D., and Reinberg, D. (2008). Ezh1 and Ezh2 maintain repressive chro-
matin through different mechanisms. Mol. Cell 32, 503–518.
Maude, S.L., Dolai, S., Delgado-Martin, C., Vincent, T., Robbins, A., Selvana-
than, A., Ryan, T., Hall, J., Wood, A.C., Tasian, S.K., et al. (2015). Efficacy of
JAK/STAT pathway inhibition in murine xenograft models of early T-cell pre-
cursor (ETP) acute lymphoblastic leukemia. Blood 125, 1759–1767.
McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller,
G.S., Liu, Y., Graves, A.P., Della Pietra, A., 3rd, Diaz, E., et al. (2012). EZH2 in-
hibition as a therapeutic strategy for lymphoma with EZH2-activating muta-
tions. Nature 492, 108–112.
McLemore, M.L., Grewal, S., Liu, F., Archambault, A., Poursine-Laurent, J.,
Haug, J., and Link, D.C. (2001). STAT-3 activation is required for normal
G-CSF-dependent proliferation and granulocytic differentiation. Immunity
14, 193–204.
Mead, A.J., Kharazi, S., Atkinson, D., Macaulay, I., Pecquet, C., Loughran, S.,
Lutteropp, M., Woll, P., Chowdhury, O., Luc, S., et al. (2013). FLT3-ITDs
instruct a myeloid differentiation and transformation bias in lymphomyeloid
multipotent progenitors. Cell Rep. 3, 1766–1776.
Mozzetta, C., Pontis, J., Fritsch, L., Robin, P., Portoso, M., Proux, C.,
Margueron, R., and Ait-Si-Ali, S. (2014). The histone H3 lysine 9 methyltrans-
ferases G9a and GLP regulate polycomb repressive complex 2-mediated
gene silencing. Mol. Cell 53, 277–289.
Muto, T., Sashida, G., Oshima, M., Wendt, G.R., Mochizuki-Kashio, M.,
Nagata, Y., Sanada,M., Miyagi, S., Saraya, A., Kamio, A., et al. (2013). Concur-
rent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic
disorders. J. Exp. Med. 210, 2627–2639.
Neff, T., Sinha, A.U., Kluk, M.J., Zhu, N., Khattab, M.H., Stein, L., Xie, H., Orkin,
S.H., and Armstrong, S.A. (2012). Polycomb repressive complex 2 is required
for MLL-AF9 leukemia. Proc. Natl. Acad. Sci. USA 109, 5028–5033.
Nikolaev, S.I., Santoni, F., Vannier, A., Falconnet, E., Giarin, E., Basso, G.,
Hoischen, A., Veltman, J.A., Groet, J., Nizetic, D., and Antonarakis, S.E.
(2013). Exome sequencing identifies putative drivers of progression of tran-
sient myeloproliferative disorder to AMKL in infants with Down syndrome.
Blood 122, 554–561.
Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M., To¨nnis-
sen, E.R., van der Heijden, A., Scheele, T.N., Vandenberghe, P., de Witte, T.,
et al. (2010). Somatic mutations of the histone methyltransferase gene EZH2
in myelodysplastic syndromes. Nat. Genet. 42, 665–667.
Novershtern, N., Subramanian, A., Lawton, L.N., Mak, R.H., Haining, W.N.,
McConkey, M.E., Habib, N., Yosef, N., Chang, C.Y., Shay, T., et al. (2011).
Densely interconnected transcriptional circuits control cell states in human
hematopoiesis. Cell 144, 296–309.
Ntziachristos, P., Tsirigos, A., Van Vlierberghe, P., Nedjic, J., Trimarchi, T.,
Flaherty, M.S., Ferres-Marco, D., da Ros, V., Tang, Z., Siegle, J., et al.
(2012). Genetic inactivation of the polycomb repressive complex 2 in T cell
acute lymphoblastic leukemia. Nat. Med. 18, 298–301.1964 Cell Reports 14, 1953–1965, March 1, 2016 ª2016 The AuthorsOguro, H., Yuan, J., Tanaka, S., Miyagi, S., Mochizuki-Kashio, M., Ichikawa,
H., Yamazaki, S., Koseki, H., Nakauchi, H., and Iwama, A. (2012). Lethal
myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor
suppressor function of the polycomb group genes. J. Exp. Med. 209, 445–454.
Okosun, J., Bo¨do¨r, C., Wang, J., Araf, S., Yang, C.Y., Pan, C., Boller, S.,
Cittaro, D., Bozek, M., Iqbal, S., et al. (2014). Integrated genomic analysis
identifies recurrent mutations and evolution patterns driving the initiation and
progression of follicular lymphoma. Nat. Genet. 46, 176–181.
Oravecz, A., Apostolov, A., Polak, K., Jost, B., Le Gras, S., Chan, S., and Kast-
ner, P. (2015). Ikaros mediates gene silencing in T cells through Polycomb
repressive complex 2. Nat. Commun. 6, 8823.
Pasini, D., Bracken, A.P., Hansen, J.B., Capillo, M., and Helin, K. (2007). The
polycomb group protein Suz12 is required for embryonic stem cell differentia-
tion. Mol. Cell. Biol. 27, 3769–3779.
Perez-Garcia, A., Ambesi-Impiombato, A., Hadler, M., Rigo, I., LeDuc, C.A.,
Kelly, K., Jalas, C., Paietta, E., Racevskis, J., Rowe, J.M., et al. (2013). Genetic
loss of SH2B3 in acute lymphoblastic leukemia. Blood 122, 2425–2432.
Pfaffl, M.W. (2001). A new mathematical model for relative quantification in
real-time RT-PCR. Nucleic Acids Res. 29, e45.
Redell, M.S., Ruiz, M.J., Gerbing, R.B., Alonzo, T.A., Lange, B.J., Tweardy,
D.J., and Meshinchi, S.; Children’s Oncology Group (2013). FACS analysis
of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prog-
nostic factor in pediatric AML: a Children’s Oncology Group report. Blood 121,
1083–1093.
Schmitt, T.M., and Zu´n˜iga-Pfl€ucker, J.C. (2002). Induction of T cell develop-
ment from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity
17, 749–756.
Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A.
(1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85,
27–37.
Shen, X., Liu, Y., Hsu, Y.J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.C., and
Orkin, S.H. (2008). EZH1 mediates methylation on histone H3 lysine 27 and
complements EZH2 in maintaining stem cell identity and executing pluripo-
tency. Mol. Cell 32, 491–502.
Shi, J., Wang, E., Zuber, J., Rappaport, A., Taylor, M., Johns, C., Lowe, S.W.,
and Vakoc, C.R. (2013). The Polycomb complex PRC2 supports aberrant self-
renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Oncogene 32, 930–938.
Shimozaki, K., Nakajima, K., Hirano, T., and Nagata, S. (1997). Involvement of
STAT3 in the granulocyte colony-stimulating factor-induced differentiation of
myeloid cells. J. Biol. Chem. 272, 25184–25189.
Simon, C., Chagraoui, J., Krosl, J., Gendron, P., Wilhelm, B., Lemieux, S.,
Boucher, G., Chagnon, P., Drouin, S., Lambert, R., et al. (2012). A key role
for EZH2 and associated genes in mouse and human adult T-cell acute leuke-
mia. Genes Dev. 26, 651–656.
Sneeringer, C.J., Scott, M.P., Kuntz, K.W., Knutson, S.K., Pollock, R.M.,
Richon, V.M., and Copeland, R.A. (2010). Coordinated activities of wild-type
plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27
on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci.
USA 107, 20980–20985.
Srinivas, S., Watanabe, T., Lin, C.S., William, C.M., Tanabe, Y., Jessell, T.M.,
and Costantini, F. (2001). Cre reporter strains produced by targeted insertion
of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1, 4.
Stieglitz, E., Taylor-Weiner, A.N., Chang, T.Y., Gelston, L.C., Wang, Y.D., Ma-
zor, T., Esquivel, E., Yu, A., Seepo, S., Olsen, S.R., et al. (2015). The genomic
landscape of juvenile myelomonocytic leukemia. Nat. Genet. 47, 1326–1333.
Su, I.H., Dobenecker, M.W., Dickinson, E., Oser, M., Basavaraj, A., Mar-
queron, R., Viale, A., Reinberg, D., W€ulfing, C., and Tarakhovsky, A. (2005).
Polycomb group protein ezh2 controls actin polymerization and cell signaling.
Cell 121, 425–436.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gil-
lette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Me-
sirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach
for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA
102, 15545–15550.
Tanaka, S., Miyagi, S., Sashida, G., Chiba, T., Yuan, J., Mochizuki-Kashio, M.,
Suzuki, Y., Sugano, S., Nakaseko, C., Yokote, K., et al. (2012). Ezh2 augments
leukemogenicity by reinforcing differentiation blockage in acute myeloid leu-
kemia. Blood 120, 1107–1117.
Treanor, L.M., Zhou, S., Janke, L., Churchman,M.L., Ma, Z., Lu, T., Chen, S.C.,
Mullighan, C.G., and Sorrentino, B.P. (2014). Interleukin-7 receptor mutants
initiate early T cell precursor leukemia in murine thymocyte progenitors with
multipotent potential. J. Exp. Med. 211, 701–713.
Tsai, M.C., Manor, O., Wan, Y., Mosammaparast, N., Wang, J.K., Lan, F., Shi,
Y., Segal, E., and Chang, H.Y. (2010). Long noncoding RNA as modular scaf-
fold of histone modification complexes. Science 329, 689–693.
Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha,
C., Sanda, M.G., Ghosh, D., Pienta, K.J., Sewalt, R.G., Otte, A.P., et al.
(2002). The polycomb group protein EZH2 is involved in progression of pros-
tate cancer. Nature 419, 624–629.
Velu, C.S., Chaubey, A., Phelan, J.D., Horman, S.R., Wunderlich, M., Guzman,
M.L., Jegga, A.G., Zeleznik-Le, N.J., Chen, J., Mulloy, J.C., et al. (2014).
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.
J. Clin. Invest. 124, 222–236.
Verhaak, R.G., Wouters, B.J., Erpelinck, C.A., Abbas, S., Beverloo, H.B.,
Lugthart, S., Lo¨wenberg, B., Delwel, R., and Valk, P.J. (2009). Prediction of
molecular subtypes in acute myeloid leukemia based on gene expression
profiling. Haematologica 94, 131–134.CeWada, H., Masuda, K., Satoh, R., Kakugawa, K., Ikawa, T., Katsura, Y., and
Kawamoto, H. (2008). Adult T-cell progenitors retain myeloid potential. Nature
452, 768–772.
Xie, H., Xu, J., Hsu, J.H., Nguyen, M., Fujiwara, Y., Peng, C., and Orkin, S.H.
(2014). Polycomb repressive complex 2 regulates normal hematopoietic
stem cell function in a developmental-stage-specific manner. Cell Stem Cell
14, 68–80.
Xu, B., On, D.M., Ma, A., Parton, T., Konze, K.D., Pattenden, S.G., Allison, D.F.,
Cai, L., Rockowitz, S., Liu, S., et al. (2015). Selective inhibition of EZH2 and
EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leu-
kemia. Blood 125, 346–357.
Yoshida, K., Toki, T., Okuno, Y., Kanezaki, R., Shiraishi, Y., Sato-Otsubo, A.,
Sanada, M., Park, M.J., Terui, K., Suzuki, H., et al. (2013). The landscape of
somatic mutations in Down syndrome-related myeloid disorders. Nat. Genet.
45, 1293–1299.
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D.,
Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012a). The genetic basis
of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157–163.
Zhang, J.A., Mortazavi, A., Williams, B.A., Wold, B.J., and Rothenberg, E.V.
(2012b). Dynamic transformations of genome-wide epigenetic marking and
transcriptional control establish T cell identity. Cell 149, 467–482.
Zhang, X., Yue, P., Page, B.D., Li, T., Zhao, W., Namanja, A.T., Paladino, D.,
Zhao, J., Chen, Y., Gunning, P.T., and Turkson, J. (2012c). Orally bioavailable
small-molecule inhibitor of transcription factor Stat3 regresses human breast
and lung cancer xenografts. Proc. Natl. Acad. Sci. USA 109, 9623–9628.ll Reports 14, 1953–1965, March 1, 2016 ª2016 The Authors 1965
